Cishe-umdlavuza / ukwelashwa / ukuhlolwa kwezilingo / umdlavuza wamasende
Izilingo Zomtholampilo Zokwelapha Umdlavuza Wamasende
Izilingo 1-4 kwezingu-4
INivolumab ne-Ipilimumab ekwelapheni iziguli ezinamathumba angajwayelekile
Lesi sigaba sesibili sokuhlolwa kwesivivinyo se-nivolumab ne-ipilimumab ekwelapheni iziguli ezinamathumba angavamile. I-Immunotherapy enama-antibody monoclonal, njenge-nivolumab ne-ipilimumab, ingasiza amasosha omzimba ukuthi ahlasele umdlavuza, futhi ingaphazamisa ikhono lamangqamuzana e-tumor ukukhula nokukhula. Lokhu kuhlolwa kubhalisa ababambiqhaza bamaqoqo alandelayo ngokuya ngesimo: 1. Izicubu ze-Epithelial ze-nasal cavity, sinuses, nasopharynx: A) I-squamous cell carcinoma enezinhlobonhlobo zomgodi wamakhala, ama-sinus, ne-nasopharynx ne-trachea (ngaphandle komdlavuza we-laryngeal, nasopharyngeal [NPC] , kanye ne-squamous cell carcinoma yekhanda nentamo [SCCHN]) B) I-Adenocarcinoma kanye nokuhlukahluka komgodi wamakhala, ama-sinus, ne-nasopharynx (kuvaliwe kuya ku-07/27/2018) 2. Izicubu ze-Epithelial zezindlala ezinkulu zamathe (zivaliwe zanda ngo-03) / 20/2018) 3. Izinduna zohlobo lwe-salivary gland ekhanda nasentanyeni, udebe, umphimbo, isisu, uqhoqhoqho namaphaphu, isifuba nenye indawo (kuvaliwe ukuze kube yisiqoqelalwazi) 4. I-carcinoma engaziwa yomgudu wamathumbu (GI) 5. I-Adenocarcinoma enezinhlobonhlobo zamathumbu amancane (avaliwe ukuze athole okwengeziwe) 05/10/2018) 6. I-squamous cell carcinoma enezinhlobo ezihlukile zepheshana le-GI (isisu esincane amathumbu, ikholoni, i-rectum, amanyikwe) (kuvaliwe kuya ku-10/17/2018) 7. I-Fibromixoma kanye ne-low grade mucinous adenocarcinoma (pseudomixoma peritonei) ye isithasiselo ne-ovary (kuvaliwe kuya ku-03/20/2018) 8. Izicubu ezivamile zepancreatic ezibandakanya i-acinar cell carcinoma, i-mucinous cystadenocarcinoma noma i-serous cystadenocarcinoma. I-Pancreatic adenocarcinoma ayifanelekile i-9.I-Intrahepatic cholangiocarcinoma (ivaliwe ukuhlangana ngo-03/20/2018) 10. Izicubu ze-Extrahepatic cholangiocarcinoma ne-bile duct (zivaliwe ukuze zande ngo-03/20/2018) 11. I-Sarcomatoid carcinoma yamaphaphu 12. I-bronchoalveolar carcinoma lung. Lesi simo manje sesibizwa nangokuthi i-adenocarcinoma in situ, i-adenocarcinoma encane, i-adenocarcinoma, noma i-mucinous adenocarcinoma 13. Izicubu ezingenayo i-epithelial ye-ovary: A) Isimila seGerm cell se-ovary B) Isigaxa seMullerian ixubene ne-adenosarcoma (ivaliwe ukwengeza ngo-03/30/2018) 14. Isigaxa se-Trophoblastic: A) I-Choriocarcinoma (ivaliwe yanda) 15. I-Transitional cell carcinoma ngaphandle kwaleyo yezinso, ukhalo, i-ureter, noma isinye (kuvalwe ukuba kube yisiqalo) 16. Isigaxa seseli ama-testes kanye nezicubu zegciwane le-extragonadal: A) I-Seminoma kanye nomdlavuza wentambo yamasende we-testicular B) Isimila esingeyona seminomatous C) I-Teratoma enenguquko ebulalayo (ivaliwe yanda) 17.
Indawo: izindawo ezingama-895
Ukuqapha Okusebenzayo, i-Bleomycin, i-Carboplatin, i-Etoposide, noma i-Cisplatin ekwelapheni iziguli zezingane kanye nabantu abadala abane-Germ Cell Tumors. . Ukuqapha okusebenzayo kungasiza odokotela ukuqapha izihloko ezinama-tumors amangqamuzana anobungozi aphansi ngemuva kokukhishwa kwesimila sabo. Izidakamizwa ezisetshenziselwa ukwelashwa ngamakhemikhali, njenge-bleomycin, i-carboplatin, i-etoposide, ne-cisplatin, zisebenza ngezindlela ezehlukene ukunqanda ukukhula kwamangqamuzana ama-tumor, kungaba ngokubulala amaseli, ngokuwavimba ekuhlukaniseni, noma ngokuwavimba ekusabalaleni. Indawo: izindawo ezingama-460
I-Inotuzumab Ozogamicin ne-Post-Induction Chemotherapy ekwelapheni iziguli ezine-High-Risk B-ALL, Mixed Phenotype Acute Leukemia, ne-B-LLy
Lesi sigaba sesivivinyo se-III sihlola ukuthi ngabe i-inotuzumab ozogamicin ingeziwe yini ekwelashweni ngamakhemikhali okwenziwa ngemuva kokungeniswa kweziguli ezine-High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) ithuthukisa imiphumela. Lesi silingo sibuye sihlole imiphumela yeziguli ezine-phenotype acute leukemia (MPAL), kanye ne-B-lymphoblastic lymphoma (B-LLy) lapho yelashwa NGONKE ukwelashwa ngaphandle kwe-inotuzumab ozogamicin. I-Inotuzumab ozogamicin iyi-anti-monoclonal antibody, ebizwa nge-inotuzumab, exhunywe nohlobo lwe-chemotherapy olubizwa nge-calicheamicin. I-Inotuzumab inamathela kumaseli womdlavuza ngendlela ehlosiwe futhi ihambisa i-calicheamicin ukuwabulala. Ezinye izidakamizwa ezisetshenziswa kuhlobo lwe-chemotherapy regimen, njenge-cyclophosphamide, i-cytarabine, i-dexamethasone, i-doxorubicin, i-daunorubicin, i-methotrexate, i-leucovorin, i-mercaptopurine, i-prednisone, i-thioguanine, i-vincristine, futhi i-pegaspargase isebenza ngezindlela ezahlukahlukene ukunqanda ukukhula kwamangqamuzana omdlavuza, kungaba ngokubulala amaseli, ngokuwavimba ekuhlukaniseni, noma ngokuwavimba ekusabalaleni. Lesi silingo sizophinda sifunde ngemiphumela yeziguli ezine-phenotype acute leukemia (MPAL) kanye nokusabalalisa i-B lymphoblastic lymphoma (B-LLy) lapho yelashwa ngengozi YONKE i-chemotherapy. Inhloso ephelele yalolu cwaningo ukuqonda ukuthi ukungeza i-inotuzumab ozogamicin ekwelashweni kokunakekelwa okujwayelekile kugcina noma kuthuthukisa imiphumela ku-High Risk B-cell Acute Lymphoblastic Leukemia (HR B-ALL). Ingxenye yokuqala yocwaningo ifaka izigaba zokuqala ezimbili zokwelashwa: Ukungeniswa kanye nokuhlanganiswa. Le ngxenye izoqoqa imininingwane nge-leukemia, kanye nemiphumela yokwelashwa kokuqala, ukuze kuhlukaniswe iziguli ngamaqembu okwelashwa okuhlanganiswa ngemuva kokuhlanganiswa. Engxenyeni yesibili yalolu cwaningo, iziguli zizothola imijikelezo ye-chemotherapy esele (ukugcinwa kwesikhashana I, ukubambezeleka kokubambezeleka, ukulungiswa kwesikhashana II, ukugcinwa), nezinye iziguli ezenzelwe ukuthola i-inotuzumab. Ezinye izinhloso zalolu cwaningo zifaka phakathi ukuphenya ukuthi ukwelashwa kwabesilisa nabesifazane isikhathi esifanayo se-chemotherapy kuyayigcina yini imiphumela yabesilisa abake baphathwa unyaka owengeziwe uma kuqhathaniswa namantombazane, kanye nokuhlola izindlela ezinhle kakhulu zokusiza iziguli ukunamathela komlomo izinhlobo zamakhemikhali. Ekugcineni, lolu cwaningo luzoba ngolokuqala ukulandelela imiphumela yezifundo nge-B-cell Lymphoblastic Leukemia (B LLy) noma iMixed Phenotype Acute Leukemia (MPAL) lapho yelashwa nge-B-ALL chemotherapy. iziguli zizothola imijikelezo ye-chemotherapy esele (ukugcinwa kwesikhashana I, ukubambezeleka kokuqina, ukulungiswa kwesikhashana II, ukugcinwa), nezinye iziguli ezenzelwe ukuthola i-inotuzumab. Ezinye izinhloso zalolu cwaningo zifaka phakathi ukuphenya ukuthi ukwelashwa kwabesilisa nabesifazane isikhathi esifanayo se-chemotherapy kuyayigcina yini imiphumela yabesilisa abake baphathwa unyaka owengeziwe uma kuqhathaniswa namantombazane, kanye nokuhlola izindlela ezinhle kakhulu zokusiza iziguli ukunamathela komlomo izinhlobo zamakhemikhali. Ekugcineni, lolu cwaningo luzoba ngolokuqala ukulandelela imiphumela yezifundo nge-B-cell Lymphoblastic Leukemia (B LLy) noma iMixed Phenotype Acute Leukemia (MPAL) lapho yelashwa nge-B-ALL chemotherapy. iziguli zizothola imijikelezo ye-chemotherapy esele (ukugcinwa kwesikhashana I, ukubambezeleka kokuqina, ukulungiswa kwesikhashana II, ukugcinwa), nezinye iziguli ezenzelwe ukuthola i-inotuzumab. Ezinye izinhloso zalolu cwaningo zifaka phakathi ukuphenya ukuthi ukwelashwa kwabesilisa nabesifazane isikhathi esifanayo se-chemotherapy kuyayigcina yini imiphumela yabesilisa abake baphathwa unyaka owengeziwe uma kuqhathaniswa namantombazane, kanye nokuhlola izindlela ezinhle kakhulu zokusiza iziguli ukunamathela komlomo izinhlobo zamakhemikhali. Ekugcineni, lolu cwaningo luzoba ngolokuqala ukulandelela imiphumela yezifundo nge-B-cell Lymphoblastic Leukemia (B LLy) noma iMixed Phenotype Acute Leukemia (MPAL) lapho yelashwa nge-B-ALL chemotherapy. Ezinye izinhloso zalolu cwaningo zifaka phakathi ukuphenya ukuthi ukwelashwa kwabesilisa nabesifazane isikhathi esifanayo se-chemotherapy kuyayigcina yini imiphumela yabesilisa abake baphathwa unyaka owengeziwe uma kuqhathaniswa namantombazane, kanye nokuhlola izindlela ezinhle kakhulu zokusiza iziguli ukunamathela komlomo izinhlobo zamakhemikhali. Ekugcineni, lolu cwaningo luzoba ngolokuqala ukulandelela imiphumela yezifundo nge-B-cell Lymphoblastic Leukemia (B LLy) noma iMixed Phenotype Acute Leukemia (MPAL) lapho yelashwa nge-B-ALL chemotherapy. Ezinye izinhloso zalolu cwaningo zifaka phakathi ukuphenya ukuthi ukwelashwa kwabesilisa nabesifazane isikhathi esifanayo se-chemotherapy kuyayigcina yini imiphumela yabesilisa abake baphathwa unyaka owengeziwe uma kuqhathaniswa namantombazane, kanye nokuhlola izindlela ezinhle kakhulu zokusiza iziguli ukunamathela komlomo izinhlobo zamakhemikhali. Ekugcineni, lolu cwaningo luzoba ngolokuqala ukulandelela imiphumela yezifundo nge-B-cell Lymphoblastic Leukemia (B LLy) noma iMixed Phenotype Acute Leukemia (MPAL) lapho yelashwa nge-B-ALL chemotherapy.
Indawo: izindawo eziyi-189
Ukusheshisa noma i-BEP Chemotherapy esheshayo noma ejwayelekile ekwelapheni iziguli ezinesisu esiphakathi noma esibi kakhulu seMetastatic Germ Cell Tumors.
Lesi silingo sesigaba III esingahleliwe sihlola ukuthi uhlelo olusheshayo lwe-bleomycin sulfate, i-etoposide phosphate, ne-cisplatin (BEP) chemotherapy isebenza kanjani uma kuqhathaniswa neshejuli ejwayelekile ye-BEP chemotherapy ekwelapheni iziguli ezinesisu esiphakathi noma esinobungozi besimila segciwane esisakazekele kwezinye izindawo emzimbeni (metastatic). Izidakamizwa ezisetshenziselwa ukwelashwa ngamakhemikhali, njenge-bleomycin sulfate, i-etoposide phosphate, ne-cisplatin, zisebenza ngezindlela ezehlukene ukunqanda ukukhula kwamangqamuzana ezimila, kungaba ngokubulala amaseli, ngokuwavimba ekuhlukaniseni, noma ngokuwavimba ekusakazeni. Ukunikeza i-BEP chemotherapy ngesivinini esisheshayo, noma "esisheshisiwe" kungasebenza kangcono ngemiphumela engemihle ekwelapheni iziguli ezinesisu esiphakathi noma esinobungozi obuphansi besimila segciwane lesandulela ngculaza uma kuqhathaniswa nohlelo olujwayelekile.
Indawo: izindawo eziyi-139
Nika amandla ukuvuselelwa okuzenzakalelayo kwamazwana